to the hospital or ICU has been recommended by national and international experts. 5, 12, 14, 31 The medical literature regarding the value of preoperative MRSA screening and MRSA-specific prophylactic antibiotics during elective neurosurgical procedures is limited. 10, 14 Gnanalingham and colleagues, 9 who noted a rise in MRSA-positive cultures in their patients from 1.9% of admissions in 1993 to 6.7% in 1999, addressed the growing importance of MRSA in neurosurgical units. They also noted that patients with MRSA infections had longer lengths of inpatient stay. Fujii and coworkers 7 investigated the mechanism of spread of MRSA from a neurosurgical patient with MRSA in the sputum, and demonstrated that horizontal surfaces in the room were more likely to harbor the bacteria than vertical surfaces, which is consistent with droplet spread. Chlorhexidine gluconate and benzalkonium chloride were more effective in disinfecting these surfaces than other commonly used disinfectants such as alkyldiaminoethyl glycine (Tego-51).
Should the prevalence of MRSA or its presence alter the selection of prophylactic antibiotics for neurosurgical procedures? Hammond and colleagues 13 compared the benefit of vancomycin to their preferred prophylactic regimen of cefuroxime plus gentamicin. Of 107 emergency admissions screened for MRSA in their study, 16 patients (15%) tested positive. Eighty-seven percent of MRSA strains were found to be susceptible to gentamicin; these authors therefore concluded that vancomycin should be reserved for patients known to be colonized with MRSA. In a region of Italy with endemic MRSA, a randomized, prospective trial for CSF shunt insertion was completed, comparing prophylactic antibiotic treatment with either cefazolin or vancomycin in 176 patients. Shunt infections occurred in 4% of patients who received vancomycin compared with 14% of those who received cefazolin. 30 All strains of Staphylococci isolated in these patients were MRSA.
We reviewed our experience with MRSA in our inpatient neurosurgical service. The Kaiser Permanente Medical Center in Sacramento is a major neurosurgery referral center that provides care for the 2 million Kaiser Permanente members in the northern Central Valley of California and emergency neurosurgical care for patients presenting to Kaiser Permanente emergency departments. The neurosurgical service accounts for approximately half of the 2171 annual ICU admissions that occur annually at our facility. All admissions to the ICU are screened for MRSA and vancomycin-resistant Enterococci under an active surveillance program. Patients were classified as MRSA positive if MRSA was identified from the nasal swab, medical record review for prior MRSA infection or colonization, or from subsequent preoperative MRSA infection. We report the clinical outcomes in these MR-SA-positive neurosurgical patients with a special focus on postoperative infections and perioperative management.
Methods
Institutional review board approval was obtained for this study. Patients under the care of the Neurosurgery Department are prospectively entered into a computerized database under a quality assurance program. The infection control department prospectively identifies and tracks MRSA-positive patients and enters this information into a separate computerized database under the infection control program. Under the Kaiser Permanente quality control program, surgical site infections and ventriculostomy infections were prospectively tracked and reported quarterly to the infection control committee, neurosurgical department, ICU, and neurocritical care directors. The research committee identified key data elements, and a retrospective chart review was completed in MRSA-positive patients using comprehensive electronic patient records. These electronic records include clinical information, laboratory data, hospital records, outpatient records, procedures, and imaging data, and they are maintained throughout the extensive northern California Kaiser network of outpatient facilities and hospitals. Our computerized data collection method facilitated data collection and chart review; consequently, no patient chart was missing from our retrospective electronic chart review.
By hospital policy, all patients admitted to the ICU underwent screening for MRSA using the nasal swab method. In addition, any patient with a prior history of a positive nasal swab for MRSA or a history of MRSA infection was classified as MRSA positive. Screening was not performed in patients admitted to non-ICU units. 
Phase II
After analysis of Phase I data, we hypothesized that perioperative care for MRSA-positive patients that included administration of prophylactic antibiotics active against MRSA (such as vancomycin) would lower the postoperative wound infection rate compared with the use of traditional prophylactic antibiotics such as cefazolin. Also after analysis of Phase I data, we standardized our postoperative wound care procedures to reduce colonization of neurosurgical wounds in ICU patients with MRSA and other nosocomial organisms. Patients received postoperative wound care according to departmental standards. For patients in the ICU, surgical incisions were covered for the first 3 days postoperatively. Wounds were then cleaned daily with chlorhexidine. If the neurosurgeon preferred that the wound be kept covered during the first 7 days, then the bandage was changed every 3 days and the wound cleaned with chlorhexidine and redressed. Maintenance of a wound dressing was recommended for posterior incisions such as suboccipital craniectomies, lumbar spine incisions, ventricular catheters, and craniotomies in patients with tracheostomies or active nosocomial infections.
From October 2005 to December 2007, the inpatient neurosurgery database of 1005 patients was reviewed for MRSA-positive patients by cross-reference to the Infection Control database. Sixty-two patients (6.2%) were MRSA positive, and MRSA status was then confirmed by review of the electronic patient chart. A detailed chart review for epidemiology and clinical course was then completed. Of the 62 patients identified, 46 underwent 55 neurosurgical procedures unrelated to their MRSA infections. We identified 5 MRSA-positive patients who underwent 7 procedures for neurosurgical infections pres ent on admission. All 5 had spine epidural abscesses with 3 caused by MRSA, 1 by Streptococcus mitis, and 1 by Mycobacterium avium-intracellulare. Because of the preexisting nature of their infections, these patients were not included in the final pooled Phase II analysis. The remaining 11 MRSA-positive neurosurgical patients did not undergo any neurosurgical procedures at our institution and were also excluded from the pooled Phase II analysis.
Statistical Analysis
Data were analyzed using commercially available software (SAS version 9.1.3; SAS Institute, Inc.). Proportions were compared using the chi-square or Fisher exact test, as appropriate. Continuous variables were compared with the Student t-test. All probability values were 2-tailed, and a p value ≤ 0.05 was considered to be statistically significant. The difference in proportions between study groups was calculated with 95% CIs.
The strength of association between study groups and outcome measures was reported as the RR with a 95% CI.
Results

Phase I
We first analyzed postoperative infections in MRSApositive neurosurgical patients admitted to the ICU between August 2006 and February 2007. We compared this population to neurosurgical ICU patients who underwent screening but were MRSA negative, and to unscreened non-ICU neurosurgical patients. The unscreened neurosurgical patients had less acute neurosurgical problems and underwent elective procedures, most frequently cervical or lumbar spine surgeries that required hospitalization.
Compared with the MRSA-negative and unscreened groups, the MRSA-positive group was more likely to have any postoperative neurosurgical wound infection, a wound infection caused by MRSA, or any MRSA infection (Tables 1 and 2 ). The details of these infections in the patients included in Phase I are listed in Table 3 . The majority of these infections involved deep surgical compartments and required hospitalization with further surgeries and extended courses of antibiotic therapy.
The rate of postoperative MRSA neurosurgical wound infection was strongly associated with MRSA-positive or -negative status ( Table 2 ). The RR for neurosurgical wound infection was 7 times higher in the MRSA-positive group than the MRSA-negative group (RR 7, 95% CI 2-26, p = 0.008). In the MRSA-positive group, 3 (75%) of 4 of cultured neurosurgical infections grew MRSA, while 1 (10%) in 10 grew MRSA in the MRSA-negative group. In addition, the overall rate of neurosurgical wound infections caused by MRSA was extremely low in the MRSAnegative group (0.4%), consistent with a low risk of nosocomial infections from MRSA. In contrast, the risk of neurosurgical wound infection from MRSA was 17.6% in the MRSA-positive group. Methicillin-resistant S. aureus was found in other wounds with local infections in this population, such as tracheostomies and decubiti.
The management of surgical site infections was determined by the treating neurosurgeon. Unless the infection was clearly limited to superficial structures, the patients returned to the operating room for wound debridement, removal of all hardware, shunts with externalization as indicated, and bone flaps. Patients received 6 weeks of antibiotics for infections that extended to the bone or led to abscess formation, and 2 weeks for infections that did not.
Phase II
Our chart review of 1005 consecutive patients who underwent neurosurgical procedures between October 2005 and December 2007 was cross-referenced with the Infection Control Database that tracks MRSA-positive patients: 62 MRSA-positive patients (6.2%) were identified and confirmed on electronic chart review. Of these 62 patients, 11 received conservative treatment, 46 un- procedures without active infections at the time of the initial procedure (Tables 4-6 ). Patients undergoing neurosurgical procedures were considered to have received MRSA-specific treatment when they received prophylactic antibiotics active against MRSA. For patients intolerant of vancomycin, other MRSA-active antibiotics were substituted. The MRSA-active prophylactic antibiotics that were administered included vancomycin in 22 procedures, linezolid in 3, daptomycin in 1, and ciprofloxacin in 1. The choice of preoperative prophylactic antibiotics was determined by the treating physician with the data available at the time of the surgery. Factors taken into consideration when selecting the preoperative antibiotic included penicillin allergy, status of MRSA screening results, and installation of hardware. After we completed Phase I at our center and presented the results to a national neurosurgery meeting, the local neurosurgeons were encouraged by the infection control staff to note the MRSA status of each patient when this result was available preoperatively and to prescribe vancomycin to MR-SA-positive patients. Because the results from nasal swab cultures require 3 days of incubation, this test result was more frequently available in clinical situations where a diagnostic evaluation was required prior to surgery. For example, a patient admitted with an intracranial enhancing solitary mass would have a nasal swab done on admission and also undergo a metastatic workup prior to operative intervention. Per hospital and national standards, vancomycin was infused 1-2 hours prior to skin incision and cephalosporin antibiotics were infused 1 hour prior to skin incision. The use of prophylactic antibiotics was closely monitored and reported quarterly by the Surgical Quality Assurance Committee.
Methicillin-resistant S. aureus-positive patients who received MRSA-specific prophylactic antibiotics were more likely to undergo a cranial procedure than a spinal procedure. We also noted a trend for patients to receive MRSA-specific prophylactic care when devices were implanted (Table 5 ). Prophylactic antibiotics administered for 28 procedures performed in 27 MRSA-negative patients included cefazolin in 27 and ceftriaxone in 1. Infections in patients who received standard prophylactic antibiotics and care were evenly distributed between cranial and spinal procedures, whereas the 2 neurosurgical infections that occurred in patients who received MRSAspecific prophylactic antibiotics occurred after cranioplasty (Tables 5 and 6 ).
Discussion
Although only a small percentage of our Phase I neurosurgical population was colonized with MRSA (6.2%), this MRSA-colonized subpopulation was at a high risk for postoperative neurosurgical wound infections, primarily from gram-positive organisms, and particularly from MRSA itself. The use of MRSA-specific prophylactic antibiotics (mainly vancomycin) was associated with a marked reduction in the risk of postoperative neurosurgical wound infections compared with the use of standard prophylactic agents (mainly cefazolin).
The results of Phase II of our study suggest that this high neurosurgical site infection rate in patients with MRSA can be significantly reduced by the use of MR-SA-specific prophylactic antibiotics such as vancomycin, compared with routinely used preoperative prophylactic antibiotics such as cefazolin, from 32.1 to 7.4% (Table 5) . Although our changes in postoperative wound care have not been formally studied, maintaining a surgical dressing for 3-7 days postoperatively in ICU patients with topical chlorhexidine wound cleaning during dressing changes to reduce the risk of MRSA self-colonization of the wound may also have been prudent.
There are a number of limitations to our study. First, only 62 patients (6.2%) on the neurosurgical service test- ed positive for MRSA. This number is too small for a meaningful examination of variables such as procedure type, duration of the procedure, and the size and location of the wound. Second, this is a retrospective, nonrandomized chart review study, which increases the risk of controlled and uncontrolled biases. Our data analysis determined that the 2 groups who received MRSA-specific or nonspecific prophylactic antibiotics were well matched except for the variables cranial procedure, device implantation, and diabetes (Tables 4 and 5 ). At our institution, cranial and spinal procedures have similar postoperative complication rates in MRSA-negative patients, so we would predict a neutral effect of increasing or decreasing the proportions of these procedures on postoperative neurosurgical wound infection rates. This is also consistent with the observation that patients who received MRSAnonspecific prophylactic antibiotics had a fairly even distribution of postoperative wound infections between cranial and spinal procedures (Tables 5 and 6 ). Patients with diabetes are known to have impaired wound healing and higher infection rates. The higher proportion of patients with diabetes in the group who received MRSA-specific antibiotics would be predicted to inflate the rate of postoperative wound infection rates (the opposite effect was observed, see Table 4 ). Despite its limitations, the present study provides a number of useful insights. The care was provided by a small number of specialists working as an integrated team in a community-based, nonacademic tertiary care center. This allowed the team to identify a specific clinical problem (neurosurgical MRSA infections) and then efficiently improve care by modifying preoperative and postoperative care. Although the selection of the preoperative antibiotic was not randomized, the study design reflects an iterative process at our center. First, we noted a high rate of surgical site infections in MRSA-colonized patients. Second, we distributed the information to our clinicians with a proposed change in practice, and third, we reviewed our data to determine whether preoperative antibiotic selection was correlated with a change in the rate of surgical site infections.
Our results suggest that it is beneficial to screen patients scheduled for complex neurosurgical and spinal procedures for MRSA colonization based on medical history and also direct culture (nasal swab, for example). We advocate that patients who test MRSA positive should receive vancomycin as the prophylactic antibiotic of choice unless there are clinical contraindications. Patients should be closely monitored for toxicity of vancomycin, particularly during the initial infusion. The so-called "red person syndrome," which begins during the infusion and is sometimes mistaken for an allergic reaction, is rare when vancomycin is infused at a slow rate (anesthesiologists may benefit from this information if they are infusing the drug over a shorter interval). Frank hypotension, severe flushing, and angioedema can occur rarely. The earlier accounts of vancomycin-associated red person syndrome, ototoxicity, and nephrotoxicity have not been seen as frequently with our current formulations of vancomycin, despite the rising use of this agent to combat the MRSA epidemic. This decrease in toxicity is generally attributed to improved purification of the antibiotic.
Brief Review of Surgical Literature
The medical literature is divided regarding the value of hospital-based MRSA screening of surgical patients. During a study of the benefits of MRSA screening in surgical patients in Switzerland, only 4 MRSA neurosurgical nosocomial infections were reported, despite a study population of 21,754 patients.
14 Of note, 29 MRSA-positive patients underwent surgical procedures: 19 received prophylactic antibiotics specific for MRSA and 10 did not, but postoperative wound infection rates for these 29 procedures were not reported. The authors concluded: "to increase effectiveness, MRSA screening could be targeted to surgical patients who undergo elective procedures with a high risk of MRSA infection." These authors also found that patients with lengthy hospitalizations on surgi- 14 At a British cardiac surgery center, 765 patients scheduled to undergo elective cardiac surgery were screened for MRSA using a same-day DNA polymerase chain reaction rapid screen test. 18 Methicillin-resistant S. aureus-positive patients received intranasal mupirocin ointment and topical triclosan, and MRSA-specific prophylactic antibiotics at the time of cardiac surgery (teicoplanin). With this active MRSA screening method, a resulting drop in MRSA infections at the cardiac surgery center was detected (RR reduction 0.77).
In other surgical specialties, MRSA wound infections are also nettlesome. Cardiac and vascular surgeons have particularly struggled with MRSA wound infections, perhaps because their patients tend to have lengthy skin incisions, poor vascular supply, and a high prevalence of diabetes. The authors of a randomized trial 21 comparing prophylaxis with 3 antibiotic regimens before cardiac and major vascular operations demonstrated postoperative wound complication rates of 3.7% with vancomycin, 12.3% with cefazolin, and 11.5% with cefamandole. Hypotension occurred in 8 of 107 patients who received vancomycin and improved with diphenhydramine and a slower rate of infusion. At the Texas Medical Center, the prophylactic antibiotic regimen was switched from cefuroxime to vancomycin, 8 and the monthly rate of surgical site infections before and after the switch was studied in 6465 patients. The rate of infections declined by 2.1 cases/100 surgeries, and no increase in wound infections from gram-negative organisms or other gram-positive or gan isms such as vancomycin-resistant Enterococcus were noted.
Conclusions
Methicillin-resistant S. aureus must be factored into the daily practice of neurosurgery. Initial antibiotic coverage for patients presenting with community-acquired neurosurgical infections, particularly abscesses in the epidural space, should be active against MRSA. Postoperative MRSA wound infections were a bigger concern than community-acquired MRSA infections at our center (70 vs 30% of total MRSA neurosurgical infections, respectively), and we found that patients with prior MRSA colonization or infection were at a high risk for this postoperative complication. We have presented data that prophylactic antibiotics active against MRSA such as vancomycin compared with standard regimens such as cefazolin can lower postoperative wound infection rates in MRSA-positive patients. In addition, wound care aimed at reducing the risk of MRSA self-colonization of the surgical wound may also be important and is simple to do. Our revised wound care practice maintains a surgical dressing while in the ICU for 3-7 days with chlorhexidine cleansing during dressing changes. With this revised wound care practice, we have seen a low intrafacility transmission rate of MRSA. For example, MRSA neurosurgical wound infections occurred in 0.4% of our MRSA-negative group compared with 17.6% of the MR-SA-positive group.
Neurosurgical centers with significant rates of postoperative neurosurgical infections caused by MRSA should consider preoperative screening for MRSA and the administration of MRSA-active prophylactic antibiotics (usually vancomycin) to MRSA-colonized patients. In some communities where MRSA colonization rates are excessive, neurosurgeons may ultimately decide on the universal use of vancomycin (or other MRSA-active antibiotics) for all neurosurgical procedures, foregoing MRSA screening altogether.
